Gilead Sciences, Inc. reported first-quarter earnings that beat analyst estimates while raising its full-year sales outlook for 2026 [1, 2].
Despite the immediate growth, the company warned that massive acquisition costs will likely lead to a loss per share by the end of the fiscal year. This creates a stark contrast between the company's operational success and its balance sheet challenges.
For the first quarter of fiscal 2026, Gilead reported adjusted earnings per share (EPS) of $2.03 [1]. This figure surpassed the Zacks consensus estimate of $1.89 [1] and represents a significant increase over the $1.00 adjusted EPS reported in the same quarter a year ago [1].
Revenue for the first quarter reached $7 billion [2], marking a four percent increase year-over-year [2]. Following these results, the company increased its full-year sales outlook by $400 million [2].
However, the long-term outlook for 2026 is clouded by substantial expenses. Gilead expects acquisition-related charges of approximately $11.5 billion [2]. These one-time costs are expected to push the company's EPS into a loss for the 2026 calendar year [1, 2].
To offset some of these pressures, the company is focusing on new product growth. Gilead has set a sales target of approximately $1 billion for Yeztugo in 2026 [3]. Additionally, the company raised its base business outlook for the year to a range between $29.4 billion and $29.8 billion [3].
“Gilead reported adjusted earnings per share (EPS) of $2.03”
Gilead is currently navigating a transition where strong organic growth and new product launches, such as Yeztugo, are being overshadowed by the high cost of corporate expansion. The projected $11.5 billion in charges suggests a major strategic pivot through acquisition that will depress short-term profitability despite a healthy base business and rising revenues.
